obesity
Page 5 of 12
LeadershipOprah to leave WeightWatchers board, donating her stake over ‘perceived conflict of interest around her taking weight loss medications’
By Amanda GerutFebruary 28, 2024
LifestyleNovo Nordisk faces competition close to home as Danish rival Zealand Pharma’s shares jump 35% on ‘groundbreaking’ weight-loss drug trial results
By Prarthana PrakashFebruary 27, 2024
RetailNovo Nordisk’s CEO says he’s fielding calls from ‘scared’ junk food suppliers asking for advice over Ozempic surge
By Ryan HoggFebruary 8, 2024
By Madison Muller and BloombergFebruary 5, 2024
By Katrina Compoli and BloombergFebruary 1, 2024
HealthWeight-loss injectables like Zepbound are making as big of a splash as Viagra, if not bigger. What you need to know about the ‘miracle drugs’
By Emma Court, Madison Muller and BloombergJanuary 31, 2024
RetailNovo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year
By Ryan HoggJanuary 31, 2024
HealthNorth Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030
By Simone Foxman, Madison Muller and BloombergJanuary 27, 2024
HealthMillions of older Americans can’t get weight loss drugs like Wegovy because Medicare won’t pay for them
By Amanda Seitz and The Associated PressDecember 28, 2023
HealthNearly half of the U.S. population has diabetes or prediabetes—and many have no clue. Are you among them?
By Erin PraterDecember 23, 2023
By Mike Stobbe and The Associated PressDecember 18, 2023
FinanceRoche pushes to catch up to Novo Nordisk’s Wegovy with $3.1bn deal for obesity drugmaker Carmot
By Paula Doenecke and BloombergDecember 4, 2023
HealthNovo Nordisk responds to U.S. rival Eli Lilly by announcing new $2.3 billion investment in France to keep up with soaring demand for weight-loss drugs
By ReutersNovember 23, 2023
By Jonel Aleccia and The Associated PressNovember 20, 2023
Most Popular
